Chapter 29 : Zygomycetes as Agents of Infectious Disease in Humans

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Zygomycetes as Agents of Infectious Disease in Humans, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815776/9781555813680_Chap29-1.gif /docserver/preview/fulltext/10.1128/9781555815776/9781555813680_Chap29-2.gif


The zygomycoses are a group of infections caused by a variety of fungal organisms belonging to the class Zygomycetes. This class is composed of two orders, Mucorales and Entomophthorales. The focus of this chapter is to discuss the molecular principles of mucormycosis pathogenesis. The agents of mucormycosis are classified into six different families based on morphologic analysis of the fungus, carbohydrate assimilation, and the maximal growth temperature. Of note, these categories of invasive mucormycosis tend to occur in patients with specific defects in host defense. The mechanism by which ketoacidosis enhances susceptibility to rhinocerebral disease remains unclear. As discussed, patients in ketoacidosis, or indeed those with any systemic acidosis, have increased available serum iron due to proton-mediated dissociation of iron from sequestering proteins. Simulated acidotic conditions decreased the iron-binding capacity of sera collected from normal volunteers. Importantly, rFTR1 gene expression is induced when is iron limited, indicating that this gene might operate in vivo where the iron supply is limited. The amdS gene allows the organism to grow on media containing acetamide as a sole source of nitrogen. These molecular approaches will aid in understanding mucormycosis pathogenesis and may therefore contribute to establishing improved therapeutic strategies to treat and/or prevent mucormycosis infections. Genome sequence data have the potential to revolutionize the study of mucormycosis, as has been done for other pathogenic fungi, including and . A recently completed genome sequence project can provide data in advancing our understanding of the pathogenesis of mucormycosis.

Citation: Ibrahim A, Spellberg B. 2006. Zygomycetes as Agents of Infectious Disease in Humans, p 428-440. In Heitman J, Filler S, Edwards, Jr. J, Mitchell A (ed), Molecular Principles of Fungal Pathogenesis. ASM Press, Washington, DC. doi: 10.1128/9781555815776.ch29
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

Taxonomy of Zygomycetes. Adapted from reference .

Citation: Ibrahim A, Spellberg B. 2006. Zygomycetes as Agents of Infectious Disease in Humans, p 428-440. In Heitman J, Filler S, Edwards, Jr. J, Mitchell A (ed), Molecular Principles of Fungal Pathogenesis. ASM Press, Washington, DC. doi: 10.1128/9781555815776.ch29
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Abe, F.,, H. Inaba,, T. Katoh, and, M. Hotchi. 1990. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia 110: 8791.
2. Abuodeh, R. O.,, M. J. Orbach,, M. A. Mandel,, A. Das, and, J. N. Galgiani. 2000. Genetic transformation of Coccidioides immitis facilitated by Agrobacterium tumefaciens. J. Infect. Dis. 181: 21062110.
3. Abzug, M. J., and, T. J. Walsh. 2004. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr. Infect. Dis. J. 23: 769773.
4. Adam, R. D.,, G. Hunter,, J. DiTomasso, and, G. Comerci, Jr. 1994. Mucormycosis: emerging prominence of cutaneous infections. Clin. Infect. Dis. 19: 6776.
5. Alsuwaida, K. 2002. Primary cutaneous mucormycosis complicating the use of adhesive tape to secure the endotracheal tube. Can. J. Anaesth. 49: 880882.
6. Anand, V. K.,, G. Alemar, and, J. A. Griswold, Jr. 1992. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope 102: 656662.
7. Anaya, N., and, M. I. Roncero. 1991. Transformation of a methionine auxotrophic mutant of Mucor circinelloides by direct cloning of the corresponding wild type gene. Mol. Gen. Genet. 230: 449455.
8. Arnau, J.,, F. J. Murillo, and, S. Torres-Martinez. 1988. Expression of Tn 5-derived kanamycin resistance in the fungus Phycomyces blakesleeanus. Mol. Gen. Genet. 212: 375377.
9. Artis, W. M.,, J. A. Fountain,, H. K. Delcher, and, H. E. Jones. 1982. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 31: 11091114.
10. Ashikari, T.,, T. Amachi,, H. Yoshizumi,, H. Horiuchi,, M. Takagi, and, K. Yano. 1990. Correct splicing of modified introns of a Rhizopus proteinase gene in Saccharomyces cerevisiae. Mol. Gen. Genet. 223: 1116.
11. Bearer, E. A.,, P. R. Nelson,, M. Y. Chowers, and, C. E. Davis. 1994. Cutaneous zygomycosis caused by Saksenaea vasiformis in a diabetic patient. J. Clin. Microbiol. 32: 18231824.
12. Benito, E. P.,, J. M. Diaz-Minguez,, E. A. Iturriaga,, V. Campuzano, and, A. P. Eslava. 1992. Cloning and sequence analysis of the Mucor circinelloides pyrG gene encoding orotidine-5’-monophosphate decarboxylase: use of pyrG for homologous transformation. Gene 116: 5967.
13. Blin, N.,, N. Morineau,, F. Gaillard,, O. Morin,, N. Milpied,, J. L. Harousseau, and, P. Moreau. 2004. Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin’s lymphoma. Leuk. Lymphoma 45: 21612163.
14. Boelaert, J. R.,, M. de Locht,, J. Van Cutsem,, V. Kerrels,, B. Cantinieaux,, A. Verdonck,, H. W. Van Landuyt, and, Y. J. Schneider. 1993. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J. Clin. Investig. 91: 19791986.
15. Boelaert, J. R.,, J. Van Cutsem,, M. de Locht,, Y. J. Schneider, and, R. R. Crichton. 1994. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 45: 667671.
16. Bouchara, J. P.,, N. A. Oumeziane,, J. C. Lissitzky,, G. Larcher,, G. Tronchin, and, D. Chabasse. 1996. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur. J. Cell Biol. 70: 7683.
17. Burmester, A.,, A. Wostemeyer,, J. Arnau, and, J. Wostemeyer. 1992. The SEG1 element: a new DNA region promoting stable mitotic segregation of plasmids in the zygomycete Absidia glauca. Mol. Gen. Genet. 235: 166172.
18. Burmester, A.,, A. Wostemeyer, and, J. Wostemeyer. 1990. Integrative transformation of a zygomycete, Absidia glauca, with vectors containing repetitive DNA. Curr. Genet. 17: 155161.
19. Cagatay, A. A.,, S. S. Oncu,, S. S. Calangu,, T. T. Yildirmak,, H. H. Ozsut, and, H. H. Eraksoy. 2001. Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect. Dis. 1: 22.
20. Chassaing, N.,, L. Valton,, M. Kany,, E. Bonnet,, E. Uro-Coste,, M. B. Delisle,, P. Bousquet, and, G. Geraud. 2003. Rhino-cerebral fungal infection successfully treated with supplementary hyperbaric oxygen therapy. Rev. Neurol. (Paris) 159: 11781180. (In French.)
21. Chen, X.,, M. Stone,, C. Schlagnhaufer, and, C. P. Romaine. 2000. A fruiting body tissue method for efficient Agrobacterium-mediated transformation of Agaricus bisporus. Appl. Environ. Microbiol. 66: 45104513.
22. Chinn, R. Y., and, R. D. Diamond. 1982. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyper-glycemia and ketoacidosis. Infect. Immun. 38: 11231129.
23. Cohen-Abbo, A.,, P. M. Bozeman, and, C. C. Patrick. 1993. Cunninghamella infections: review and report of two cases of Cunninghamella pneumonia in immuno-compromised children. Clin. Infect. Dis. 17: 173177.
24. Couch, L.,, F. Theilen, and, J. T. Mader. 1988. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch. Otolaryngol. Head Neck Surg. 114: 791794.
25. Dannaoui, E.,, J. F. Meis,, D. Loebenberg, and, P. E. Verweij. 2003. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother. 47: 36473650.
26. Dannaoui, E.,, J. Meletiadis,, J. W. Mouton,, J. F. Meis, and, P. E. Verweij. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51: 4552.
27. de Groot, M. J.,, P. Bundock,, P. J. Hooykaas, and, A. G. Beijersbergen. 1998. Agrobacterium tumefaciens- mediated transformation of filamentous fungi. Nat. Biotechnol. 16: 839842.
28. de Locht, M.,, J. R. Boelaert, and, Y. J. Schneider. 1994. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem. Pharmacol. 47: 18431850.
29. Del Poeta, M.,, W. A. Schell, and, J. R. Perfect. 1997. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41: 18351836.
30. Diamond, R. D.,, C. C. Haudenschild, and, N. F. Erickson III. 1982. Monocyte-mediated damage to Rhizopus oryzae hyphae in vitro. Infect. Immun. 38: 292297.
31. Eisen, D. P., and, J. Robson. 2004. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses 47: 159162.
32. Eiser, A. R.,, R. F. Slifkin, and, M. S. Neff. 1987. Intestinal mucormycosis in hemodialysis patients following deferoxamine. Am. J. Kidney Dis. 10: 7173.
33. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36: 29502956.
34. Farley, P. C., and, P. A. Sullivan. 1998. The Rhizopus oryzae secreted aspartic proteinase gene family: an analysis of gene expression. Microbiology 144: 23552366.
35. Fu, Y.,, H. Lee,, M. Collins,, H. F. Tsai,, B. Spellberg,, J. E. Edwards, Jr.,, K. J. Kwon-Chung, and, A. S. Ibrahim. 2004. Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol. Lett. 235: 169176.
36. Garcia-Covarrubias, L.,, D. M. Barratt,, R. Bartlett, and, K. Van Meter. 2004. Treatment of mucormycosis with adjunctive hyperbaric oxygen: five cases treated at the same institution and review of the literature. Rev. Investig. Clin. 56: 5155. (In Spanish.)
37. Gartenberg, G.,, E. J. Bottone,, G. T. Keusch, and, I. Weitzman. 1978. Hospital-acquired mucormycosis ( Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N. Engl. J. Med. 299: 11151118.
38. Gleissner, B.,, A. Schilling,, I. Anagnostopolous,, I. Siehl, and, E. Thiel. 2004. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma 45: 13511360.
39. Groll, A. H.,, N. Giri,, V. Petraitis,, R. Petraitiene,, M. Candelario,, J. S. Bacher,, S. C. Piscitelli, and, T. J. Walsh. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182: 274282.
40. Holzberg, M., and, W. M. Artis. 1983. Hydroxamate siderophore production by opportunistic and systemic fungal pathogens. Infect. Immun. 40: 11341139.
41. Horiuchi, H.,, T. Ashikari,, T. Amachi,, H. Yoshizumi,, M. Takagi, and, K. Yano. 1990. High-level secretion of a Rhizopus niveus aspartic proteinase in Saccharomyces cerevisiae. Agric. Biol. Chem. 54: 17711779.
42. Horiuchi, H.,, N. Takaya,, K. Yanai,, M. Nakamura,, A. Ohta, and, M. Takagi. 1995. Cloning of the Rhizopus niveus pyr4 gene and its use for the transformation of Rhizopus delemar. Curr. Genet. 27: 472478.
43. Ibrahim, A. S.,, V. Avanessian,, B. Spellberg, and, J. E. Edwards, Jr. 2003. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob. Agents Chemother. 47: 33433344.
44. Ibrahim, A. S.,, J. C. Bowman,, V. Avanessian,, K. Brown,, B. Spellberg,, J. J. Edwards, and, C. M. Douglas. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-β-D glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49: 721727.
45. Ibrahim, A. S.,, J. E. J. Edwards, and, S. G. Filler. 2003. Zygomycosis, p. 241–251. In W. E. Dismukes,, P. G. Pappas, and, J. D. Sobel (ed.), Clinical Mycology. Oxford University Press, New York, N.Y.
46. Ibrahim, A. S.,, B. J. Spellberg,, V. Avanessian,, Y. Fu, and, J. Edwards, Jr. 2005. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect. Immun. 73: 778783.
47. Ide, L.,, I. Buysschaert,, H. Demuynck,, R. De Man,, A. Verlinde,, E. De Laere, and, I. Surmont. 2004. Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole? Clin. Microbiol. Infect. 10: 862863.
48. Imhof, A.,, S. A. Balajee,, D. N. Fredricks,, J. A. Englund, and, K. A. Marr. 2004. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39: 743746.
49. Jacobs, P.,, L. Wood,, A. Du Toit, and, K. Esterhuizen. 2003. Eradication of invasive mucormycosis— effectiveness of the echinocandin FK463. Hematology 8: 119123.
50. Kamalam, A., and, A. S. Thambiah. 1980. Cutaneous infection by Syncephalastrum. Sabouraudia 18: 1920.
51. Kauffman, C. A. 2004. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis. 39: 588590.
52. Kemna, M. E.,, R. C. Neri,, R. Ali, and, I. F. Salkin. 1994. Cokeromyces recurvatus, a mucoraceous zygomycete rarely isolated in clinical laboratories. J. Clin. Microbiol. 32: 843845.
53. Kerr, O. A.,, C. Bong,, C. Wallis, and, M. J. Tidman. 2004. Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br. J. Dermatol. 150: 12121213.
54. Khor, B. S.,, M. H. Lee,, H. S. Leu, and, J. W. Liu. 2003. Rhinocerebral mucormycosis in Taiwan. J. Microbiol. Immunol. Infect. 36: 266269.
55. Kohno, M.,, M. Enatsu, and, W. Kugimiya. 1998. Cloning of genomic DNA of Rhizopus niveus lipase and expression in the yeast Saccharomyces cerevisiae. Biosci. Biotechnol. Biochem. 62: 24252427.
56. Kontoyiannis, D. P.,, S. Vartivarian,, E. J. Anaissie,, G. Samonis,, G. P. Bodey, and, M. Rinaldi. 1994. Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin. Infect. Dis. 18: 925928.
57. Kontoyiannis, D. P.,, V. C. Wessel,, G. P. Bodey, and, K. V. Rolston. 2000. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin. Infect. Dis. 30: 851856.
58. Kwon-Chung, K. J., and, J. E. Bennett. 1992. Mucormycosis, p. 524–559. In Medical Mycology. Lea & Febiger, Philadelphia, Pa.
59. Kwon-Chung, K. J.,, R. C. Young, and, M. Orlando. 1975. Pulmonary mucormycosis caused by Cunninghamella elegans in a patient with chronic myelogenous leukemia. Am. J. Clin. Pathol. 64: 544548.
60. Larsen, K.,, C. von Buchwald,, B. Ellefsen, and, D. Francis. 2003. Unexpected expansive paranasal sinus mucormycosis. J. Otorhinolaryngol. Relat. Spec. 65: 5760.
61. Lee, F. Y.,, S. B. Mossad, and, K. A. Adal. 1999. Pulmonary mucormycosis: the last 30 years. Arch. Intern. Med. 159: 13011309.
62. Liou, C. M.,, K. Yanai,, H. Horiuchi, and, M. Takagi. 1992. Transformation of a Leu mutant of Rhizopus niveus with the leuA gene of Mucor circinelloides. Biosci. Biotechnol. Biochem. 56: 15031504.
63. Long, D. M.,, E. D. Smidansky,, A. J. Archer, and, G. A. Strobel. 1998. In vivo addition of telomeric repeats to foreign DNA generates extrachromosomal DNAs in the taxol-producing fungus Pestalotiopsis microspora. Fungal Genet. Biol. 24: 335344.
64. Lye, G. R.,, G. Wood, and, G. Nimmo. 1996. Subcutaneous zygomycosis due to Saksenaea vasiformis: rapid isolate identification using a modified sporulation technique. Pathology 28: 364365.
65. Mackenzie, D. A.,, P. Wongwathanarat,, A. T. Carter, and, D. B. Archer. 2000. Isolation and use of a homologous histone H4 promoter and a ribosomal DNA region in a transformation vector for the oil-producing fungus Mortierella alpina. Appl. Environ. Microbiol. 66: 46554661.
66. Maertens, J.,, H. Demuynck,, E. K. Verbeken,, P. Zachée,, G. E. Verhoef,, P. Vandenberghe, and, M. A. Boogaerts. 1999. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 24: 307312.
67. Marr, K. A.,, R. A. Carter,, F. Crippa,, A. Wald, and, L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34: 909917.
68. Marty, F. M.,, L. A. Cosimi, and, L. R. Baden. 2004. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350: 950952.
69. McAdams, H. P.,, M. Rosado de Christenson,, D. C. Strollo, and, E. F. Patz, Jr. 1997. Pulmonary mucormycosis: radiologic findings in 32 cases. Am. J. Roentgenol. 168: 15411548.
70. McNulty, J. S. 1982. Rhinocerebral mucormycosis: predisposing factors. Laryngoscope 92: 11401143.
71. Mead, J. H.,, G. P. Lupton,, C. L. Dillavou, and, R. B. Odom. 1979. Cutaneous Rhizopus infection. Occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA 242: 272274.
72. Michielse, C. B.,, K. Salim,, P. Ragas,, A. F. Ram,, B. Kudla,, B. Jarry,, P. J. Punt, and, C. A. van den Hondel. 2004. Development of a system for integrative and stable transformation of the zygomycete Rhizopus oryzae by Agrobacterium-mediated DNA transfer. Mol. Genet. Genomics 271: 499510.
73. Monfort, A.,, L. Cordero,, S. Maicas, and, J. Polaina. 2003. Transformation of Mucor miehei results in plasmid deletion and phenotypic instability. FEMS Microbiol. Lett. 224: 101106.
74. Navarro, E.,, J. M. Lorca-Pascual,, M. D. Quiles-Rosillo,, F. E. Nicolas,, V. Garre,, S. Torres-Martinez, and, R. M. Ruiz-Vazquez. 2001. A negative regulator of light-inducible carotenogenesis in Mucor circinelloides. Mol. Genet. Genomics 266: 463470.
75. Nithyanandam, S.,, M. S. Jacob,, R. R. Battu,, R. K. Thomas,, M. A. Correa, and, O. D’Souza. 2003. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian. J. Ophthalmol. 51: 231236.
76. Parfrey, N. A. 1986. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine 65: 113123.
77. Pavie, J.,, M. Lafaurie,, C. Lacroix,, A. Marie Zagdanski,, D. Debrosse,, G. Socie,, F. Derouin,, E. Gluckman, and, J. Michel Molina. 2004. Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy. Scand. J. Infect. Dis. 36: 767769.
78. Peterson, K. L.,, M. Wang,, R. F. Canalis, and, E. Abemayor. 1997. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope 107: 855862.
79. Petrikkos, G.,, A. Skiada,, H. Sambatakou,, A. Toskas,, G. Vaiopoulos,, M. Giannopoulou, and, N. Katsilambros. 2003. Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur. J. Clin. Microbiol. Infect. Dis. 22: 753756.
80. Pfaller, M. A.,, S. A. Messer,, R. J. Hollis, and, R. N. Jones. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46: 10321037.
81. Ponz, E.,, J. M. Campistol,, T. Ribalta,, J. Montoliú,, J. Ramírez,, J. Almirall, and, L. Revert. 1991. Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine. Rev. Clin. Esp. 188: 8587. (In Spanish).
82. Powell, W. A., and, H. C. Kistler. 1990. In vivo rearrangement of foreign DNA by Fusarium oxysporum produces linear self-replicating plasmids. J. Bacteriol. 172: 31633171.
83. Quinio, D.,, A. Karam,, J. P. Leroy,, M. C. Moal,, B. Bourbigot,, O. Masure,, B. Sassolas, and, A. M. Le Flohic. 2004. Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant recipient. Med. Mycol. 42: 177180.
84. Ribes, J. A.,, C. L. Vanover-Sams, and, D. J. Baker. 2000. Zygomycetes in human disease. Clin. Microbiol. Rev. 13: 236301.
85. Rickerts, V.,, A. Bohme, and, G. Just-Nubling. 2002. Risk factor for invasive zygomycosis in patients with hemato-logic malignancies. Mycoses 45(Suppl. 1) : 2730.
86. Robb, S. M. 1966. Reactions of fungi to exposure to 10 atmospheres pressure of oxygen. J. Gen. Microbiol. 45: 1729.
87. Ruiz-Hidalgo, M. J.,, A. P. Eslava,, M. I. Alvarez, and, E. P. Benito. 1999. Heterologous expression of the Phycomyces blakesleeanus phytoene dehydrogenase gene ( carB) in Mucor circinelloides. Curr. Microbiol. 39: 259264.
88. Safdar, A.,, S. O’Brien, and, I. F. Kouri. 2004. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant. 34: 467468.
89. Siwek, G. T.,, K. J. Dodgson,, M. de Magalhaes-Silverman,, L. A. Bartelt,, S. B. Kilborn,, P. L. Hoth,, D. J. Diekema, and, M. A. Pfaller. 2004. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis. 39: 584587.
90. Skory, C. D. 2002. Homologous recombination and double-strand break repair in the transformation of Rhizopus oryzae. Mol. Genet. Genomics 268: 397406.
91. Spellberg, B.,, Y. Fu,, J. Edwards, Jr., and, A. S. Ibrahim. 2005. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob. Agents Chemother. 49: 830832.
92. Sugar, A. M. 1995. Agent of mucormycosis and related species, p. 2311–2321. In G. Mandell,, J. Bennett, and, R. Dolin (ed.), Principles and Practices of Infectious Diseases, 4th ed. Churchill Livingstone, New York, N.Y.
93. Sun, Q. N.,, A. W. Fothergill,, D. I. McCarthy,, M. G. Rinaldi, and, J. R. Graybill. 2002. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46: 15811582.
94. Sun, Q. N.,, L. K. Najvar,, R. Bocanegra,, D. Loebenberg, and, J. R. Graybill. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46: 23102312.
95. Takaya, N.,, K. Yanai,, H. Horiuchi,, A. Ohta, and, M. Takagi. 1996. Cloning and characterization of the Rhizopus niveus leu1 gene and its use for homologous transformation. Biosci. Biotechnol. Biochem. 60: 448452.
96. Tedder, M.,, J. A. Spratt,, M. P. Anstadt,, S. S. Hegde,, S. D. Tedder, and, J. E. Lowe. 1994. Pulmonary mucormycosis: results of medical and surgical therapy. Ann. Thorac. Surg. 57: 10441050.
97. Teggi, A.,, A. Fedele,, R. Bagnato,, F. Traditi,, C. M. Lanzalone, and, F. De Rosa. 1989. A case of disseminated mucormycosis. Rec. Prog. Med. 80: 308313.
98. Tobon, A. M.,, M. Arango,, D. Fernandez, and, A. Restrepo. 2003. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin. Infect. Dis. 36: 14881491.
99. Van Cutsem, J., and, J. R. Boelaert. 1989. Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int. 36: 10611068.
100. Van Cutsem, J.,, F. Van Gerven,, J. Fransen, and, P. A. Janssen. 1989. Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B. Chemotherapy 35: 267272.
101. Ventura, G. J.,, H. M. Kantarjian,, E. Anaissie,, R. L. Hopfer, and, V. Fainstein. 1986. Pneumonia with Cunninghamella species in patients with hematologic malignancies. A case report and review of the literature. Cancer 58: 15341536.
102. Verweij, P. E.,, A. Voss,, J. P. Donnelly,, B. E. de Pauw, and, J. F. Meis. 1997. Wooden sticks as the source of a pseudoepidemic of infection with Rhizopus microsporus var. rhizopodiformis among immunocompromised patients. J. Clin. Microbiol. 35: 24222423.
103. Voitl, P.,, C. Scheibenpflug,, T. Weber,, O. Janata, and, A. M. Rokitansky. 2002. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 21: 632634.
104. Wada, M.,, T. Beppu, and, S. Horinouchi. 1996. Integrative transformation of the zygomycete Rhizomucor pusillus by homologous recombination. Appl. Microbiol. Biotechnol. 45: 652657.
105. Waldorf, A. R. 1989. Pulmonary defense mechanisms against opportunistic fungal pathogens. Immunol. Ser. 47: 243271.
106. Waldorf, A. R., and, R. D. Diamond. 1984. Cerebral mucormycosis in diabetic mice after intrasinus challenge. Infect. Immun. 44: 194195.
107. Waldorf, A. R.,, C. Halde, and, N. A. Vedros. 1982. Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia 20: 217224.
108. Waldorf, A. R.,, S. M. Levitz, and, R. D. Diamond. 1984. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J. Infect. Dis. 150: 752760.
109. Waldorf, A. R.,, N. Ruderman, and, R. D. Diamond. 1984. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J. Clin. Investig. 74: 150160.
110. Weng, D. E.,, W. H. Wilson,, R. Little, and, T. J. Walsh. 1998. Successful medical management of isolated renal zygomycosis: case report and review. Clin. Infect. Dis. 26: 601605.
111. Woods, J. P., and, W. E. Goldman. 1993. Autonomous replication of foreign DNA in Histoplasma capsulatum: role of native telomeric sequences. J. Bacteriol. 175: 636641.
112. Wostemeyer, J.,, A. Burmester, and, C. Weigel. 1987. Neomycin resistance as a dominantly selectable marker for transformation of the zygomycete Absidia glauca. Curr. Genet. 12: 625627.
113. Yamazaki, H.,, Y. Ohnishi,, K. Takeuchi,, N. Mori,, N. Shiraishi,, Y. Sakata,, H. Suzuki, and, S. Horinouchi. 1999. Genetic transformation of a Rhizomucor pusillus mutant defective in asparagine-linked glycosylation: production of a milk-clotting enzyme in a less-glycosylated form. Appl. Microbiol. Biotechnol. 52: 401409.
114. Yanai, K.,, H. Horiuchi,, M. Takagi, and, K. Yano. 1991. Transformation of Rhizopus niveus using a bacterial blasticidin S resistance gene as a dominant selectable marker. Curr. Genet. 19: 221226.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error